{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:30:20Z","timestamp":1788867020590,"version":"build-2803163510"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["202300410249"],"award-info":[{"award-number":["202300410249"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Gefitinib is mainly used for the treatment of non-small-cell lung cancer. Hepatotoxicity is one of the main side effects of gefitinib, and seriously affects the treatment process of the disease. However, the hepatotoxicity mechanism of gefitinib remains unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The hepatotoxicity of different doses of gefitinib was investigated in mice and AML-12 cells, and the possible correlation of hepatotoxicity with CYP450 was analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>The toxic effects of gefitinib were confirmed by the increased liver index, decreased body weight and survival rate, injured liver function and histopathology followed 16 days of oral administration. Gefitinib (400 mg\/kg) upregulated the hepatic mRNA expression of CYP1A1 and downregulated the CYP2D9 and CYP2D10 in mice. Furthermore, we verified that gefitinib produced cytotoxicity on AML-12 cells in a dose and time-dependent manner, and confirmed that gefitinib (20 \u03bcM) induced cell apoptosis, upregulated mRNA expression of CYP1A1 and downregulated CYP2D9 and CYP2D10. Pearson correlation analysis also showed that the hepatotoxicity of gefitinib was positively correlated with CYP1A1 and negatively correlated with CYP2D9 and CYP2D10.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results suggested that the hepatotoxicity gefitinib may be associated with CYP1A1, CYP2D9 and CYP2D10. These findings will contribute to a better understanding of the mechanism of gefitinib hepatotoxicity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jpp\/rgac091","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T14:40:25Z","timestamp":1674139225000},"page":"407-414","source":"Crossref","is-referenced-by-count":7,"title":["Study on the hepatotoxicity and potential mechanism of gefitinib based on CYP450 in mice and AML12 cells"],"prefix":"10.1093","volume":"75","author":[{"given":"Xiaoting","family":"Yin","sequence":"first","affiliation":[{"name":"Henan Key Laboratory for Modern Research on Zhongjing\u2019s Herbal Formulae, Academy of Chinese Medical Sciences, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]},{"name":"College of Pharmacy, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzhen","family":"Ma","sequence":"additional","affiliation":[{"name":"College of Basic Medicine, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Li","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Modern Research on Zhongjing\u2019s Herbal Formulae, Academy of Chinese Medical Sciences, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]},{"name":"College of Pharmacy, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaifei","family":"Lu","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Modern Research on Zhongjing\u2019s Herbal Formulae, Academy of Chinese Medical Sciences, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]},{"name":"College of Pharmacy, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Modern Research on Zhongjing\u2019s Herbal Formulae, Academy of Chinese Medical Sciences, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]},{"name":"College of Pharmacy, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Modern Research on Zhongjing\u2019s Herbal Formulae, Academy of Chinese Medical Sciences, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]},{"name":"College of Pharmacy, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyin","family":"Li","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Modern Research on Zhongjing\u2019s Herbal Formulae, Academy of Chinese Medical Sciences, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]},{"name":"College of Pharmacy, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Su","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Modern Research on Zhongjing\u2019s Herbal Formulae, Academy of Chinese Medical Sciences, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Bai","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Modern Research on Zhongjing\u2019s Herbal Formulae, Academy of Chinese Medical Sciences, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4611-8314","authenticated-orcid":false,"given":"Yucheng","family":"Li","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory for Modern Research on Zhongjing\u2019s Herbal Formulae, Academy of Chinese Medical Sciences, Henan University of Chinese Medicine , Zhengzhou 450046 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"2024103012213242000_CIT0001","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrd1136","article-title":"Gefitinib","volume":"2","author":"Muhsin","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"2024103012213242000_CIT0002","first-page":"1404","article-title":"Therapeutic effect of gefitinib in advanced non-small cell lung cancer and its effect on the EGFR level in peripheral blood","volume":"22","author":"Wang","year":"2017","journal-title":"J BUON"},{"key":"2024103012213242000_CIT0003","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/jnci\/djj469","article-title":"Pharmacogenetics of ABCG2 and adverse reactions to gefitinib","volume":"98","author":"Cusatis","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"2024103012213242000_CIT0004","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/14740338.2016.1192605","article-title":"Safety of gefitinib in non-small cell lung cancer treatment","volume":"15","author":"Hsiue","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2024103012213242000_CIT0005","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/0003-9861(58)90436-3","article-title":"Pigments of rat liver microsomes","volume":"75","author":"Klingenberg","year":"1958","journal-title":"Arch Biochem Biophys"},{"key":"2024103012213242000_CIT0006","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1389450118666170125144557","article-title":"Cytochrome P450 structure, function and clinical significance: a review","volume":"19","author":"Manikandan","year":"2018","journal-title":"Curr Drug Targets"},{"key":"2024103012213242000_CIT0007","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2174\/1389200221666200817113920","article-title":"A review: effects of macrolides on CYP450 enzymes","volume":"21","author":"Zhang","year":"2020","journal-title":"Curr Drug Metab"},{"key":"2024103012213242000_CIT0008","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"2024103012213242000_CIT0009","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024103012213242000_CIT0010","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2165\/00003088-200544110-00004","article-title":"Single-dose clinical pharmacokinetic studies of gefitinib","volume":"44","author":"Swaisland","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2024103012213242000_CIT0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2013.09.005","article-title":"Evaluation of abnormal liver tests","volume":"98","author":"Woreta","year":"2014","journal-title":"Med Clin North Am"},{"key":"2024103012213242000_CIT0012","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.3390\/ijms15046990","article-title":"Drug-induced hepatotoxicity: metabolic, genetic and immunological basis","volume":"15","author":"Njoku","year":"2014","journal-title":"Int J Mol Sci"},{"key":"2024103012213242000_CIT0013","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cllc.2013.03.003","article-title":"Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity","volume":"14","author":"Takimoto","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"2024103012213242000_CIT0014","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1568009620666201006143419","article-title":"The activation of procarcinogens by CYP1A1\/1B1 and related chemo-preventive agents: a review","volume":"21","author":"Li","year":"2021","journal-title":"Curr Cancer Drug Targets"},{"key":"2024103012213242000_CIT0015","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.3390\/molecules27072224","article-title":"Metabolomic profiling reveals protective effects and mechanisms of sea buckthorn sterol against carbon tetrachloride-induced acute liver injury in rats","volume":"27","author":"Sheng","year":"2022","journal-title":"Molecules"},{"key":"2024103012213242000_CIT0016","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1542\/peds.113.S3.1097","article-title":"Liver","volume":"113","author":"Pineiro-Carrero","year":"2004","journal-title":"Pediatrics"},{"key":"2024103012213242000_CIT0017","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2019.11.006","article-title":"Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer","volume":"125","author":"Leighl","year":"2020","journal-title":"Eur J Cancer"},{"key":"2024103012213242000_CIT0018","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1080\/15548627.2020.1851492","article-title":"PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1)","volume":"17","author":"Luo","year":"2021","journal-title":"Autophagy"},{"key":"2024103012213242000_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxlet.2021.02.003","article-title":"Mechanism of hepatotoxicity of first-line tyrosine kinase inhibitors: gefitinib and afatinib","volume":"343","author":"Zhang","year":"2021","journal-title":"Toxicol Lett"},{"key":"2024103012213242000_CIT0020","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-04-0058","article-title":"Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy","volume":"10","author":"Wolf","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2024103012213242000_CIT0021","first-page":"1115","article-title":"\u4eba\u809d\u810f\u4e2dCYP1A1\u7684\u9ad8\u53ef\u53d8\u8868\u8fbe\u4ee5\u53ca\u5bf9\u4eba\u4e2d\u745e\u897f\u5471\u548c\u683c\u62c9\u53f8\u743c\u836f\u4ee3\u52a8\u529b\u5b66\u7684\u5f71\u54cd","volume":"32","author":"Lang","year":"2019","journal-title":"\u5316\u5b66\u7814\u7a76\u6bd2\u7406\u5b66"},{"key":"2024103012213242000_CIT0022","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2131\/jts.46.167","article-title":"Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury","volume":"46","author":"Shimizu","year":"2021","journal-title":"J Toxicol Sci"},{"key":"2024103012213242000_CIT0023","doi-asserted-by":"crossref","first-page":"115394","DOI":"10.1016\/j.jep.2022.115394","article-title":"Ginsenoside Rg1 protects mice against 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced liver injury by inhibiting CYP1A1 through the aryl hydrocarbon receptor","volume":"294","author":"Li","year":"2022","journal-title":"J Ethnopharmacol"},{"key":"2024103012213242000_CIT0024","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.toxlet.2017.03.028","article-title":"Pregnane X receptor regulates the AhR\/Cyp1A1 pathway and protects liver cells from benzo-[alpha]-pyrene-induced DNA damage","volume":"275","author":"Cui","year":"2017","journal-title":"Toxicol Lett"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/75\/3\/407\/60218229\/rgac091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/75\/3\/407\/60218229\/rgac091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T17:18:29Z","timestamp":1730308709000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/75\/3\/407\/6992890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,1]]},"published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgac091","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2023,3,1]]}}}